MedTrace Logo

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

NCT00769119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).

Conditions

Interventions

DRUG

AZD9668

2 x 30 mg, oral tablet, twice daily for 28 days

DRUG

Placebo

2 x Matched placebo, oral tablet, twice daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Stockley, Prof · Queen Elizabeth Hospital, Birmingham, England

  • Carin Jorup · AstraZeneca R&D Lund

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769119 on ClinicalTrials.gov